Involvement of HERVs in Neurological Diseases {#s1}
=============================================

Up to 8% of the human genome are of retroviral origin. These retroviral elements, termed human endogenous retroviruses (HERVs), invaded the germ line millions of years ago and have been permanently integrated into the genome of our primate ancestors ([@B38]). Following integration, retrotransposonal activity led to the amplification of these retroviral elements ([@B6]). While most of these retroviral genes contain intragenic deletions or nonsense mutations and are therefore presumed to be silent, some of them retained parts of their functionality and developed into enhancers of the immune defense ([@B30]). Other genes, such as syncytin encoded by ERVWE1, a full length provirus at locus 7q21.2 on chromosome 7, were domesticated and act in placental development ([@B57]). HERV elements may normally be expressed at low levels, but environmental factors, such as hypoxia ([@B10]), drugs ([@B42]), other viruses ([@B41]), and certain mutations ([@B80]), were shown to increase their expression. Importantly, several studies were able to show that inflammation plays a major role in HERV activation ([@B46]; [@B47]; [@B39]; [@B52]; [@B51];[@B32]). However, current research indicates that HERVs are also associated with several neurological disorders such as multiple sclerosis (MS; [@B60]), amyotrophic lateral sclerosis (ALS; [@B54]), and schizophrenia (SCZ; [@B79]), which warrants research into underlying mechanisms of activation as well as into their role in disease etiology. As underlying disease causes of many neurological conditions remain elusive, HERV-directed research might shed light on new interactions and pathological processes implicated into disease onset or progression. These entities, which are *sensu stricto* neither viruses nor physiological genes, must therefore be considered as a new category of pathogenic elements ([@B23]). In the present review, we will summarize what is currently known about the involvement of HERVs in neurological diseases and will specifically address functions exerted on neurons and glial cells of the central nervous system (CNS).

Of note, HERV-W has been associated, repeatedly and based on a larger number of independent studies, with MS as recently reviewed in ([@B17]). This demyelinating CNS disease of unknown etiology features miscellaneous clinical symptoms such as sensory, motor, and cognitive dysfunctions. Pathophysiologically, MS is characterized by immune cell infiltration, focal inflammation, and loss of myelin sheaths, leading to white and gray matter lesions and brain atrophy ([@B67]). Axonal degeneration, observed mainly but not exclusively during progression and later disease stages ([@B72]), is another of its hallmarks and results in irreversible deficits. Mechanistically, direct autoimmune attacks on neurons ([@B14]) as well as secondary effects in response to myelin loss are responsible for axonal impairment and loss. In 1989, an association between retroviral elements and MS was described based on the analysis of primary leptomeningeal cell cultures isolated from MS patients ([@B60]). While these isolated viral particles were initially termed multiple sclerosis associated retrovirus (MSRV), it was later found that MSRV belongs, in fact, to the HERV family ([@B18]; [@B58]). Follow-up studies provided convincing evidence that activation and expression of otherwise dormant HERV-W DNA sequences and the subsequent production of the encoded envelope (ENV) protein can trigger an immune response ([@B62]; [@B68]). Moreover, it was shown that HERV-W ENV RNA and protein levels are increased in the cerebrospinal fluid (CSF) and serum of MS patients but rarely in healthy individuals ([@B25]; [@B48]; [@B61]). Furthermore, it was shown that HERV-W ENV activates the innate immunity, priming it against myelin proteins. Accordingly, HERV-W ENV can act as an adjuvant in a model of experimental autoimmune encephalitis (EAE), which, in turn, can be rescued by the application of an HERV-W ENV-targeted therapeutic IgG4 antibody termed GNbAC1 (EAE; [@B59]). MS histology then revealed that the HERV-W ENV protein is mainly expressed by myeloid cells ([@B36]; [@B75]). Of note, a similar correlation was observed for HERV-W and chronic inflammatory demyelinating polyneuropathy (CIDP), an inflammatory, demyelinating disease of the peripheral nervous system (PNS; [@B22]).

Apart from roles in cancer ([@B29]) HERV-K also appears to be involved in a subpopulation of patients with sporadic ALS. This neurodegenerative disease is characterized by the progressive loss of both cortical and spinal motor neurons ([@B53]). Although first described in the 19th century, its pathogenesis is still poorly understood despite considerable efforts to identify causes and susceptibilities in recent decades. Elevated HERV-K reverse transcriptase (RT) activity was observed in both blood and CSF from ALS patients ([@B43]; [@B54]). So far, two loci could be identified in the 7q34 and 7q36.1 regions, leading to the expression of HERV-K elements in ALS patients ([@B24]). Initial analysis of brain autopsy tissue revealed the expression of several HERV-K transcripts in cortical and spinal neurons of ALS but not in healthy control individuals ([@B20]). Although evidence for such an involvement is increasing ([@B56]), it is currently challenged by a recent independent study that was not able to confirm the association between elevated cortical HERV-K RNA levels and ALS ([@B26]). Despite these conflicting observations related to the detection in ALS, it must be emphasized that transgenic mice expressing the HERV-K envelope protein display progressive motor dysfunction and motor cortex volume loss ([@B39]).

SCZ is a complex neuropsychiatric disorder characterized by a variety of cognitive, emotional, and perceptual disturbances. Pathophysiologically, SCZ features decreased brain volume, loss of myelin, and altered astrocyte function ([@B5]). In contrast to MS and ALS, both HERV-W and HERV-K have been weakly linked to SCZ based on PCR amplification from CSF and post-mortem brains as well as on protein antigenemia ([@B79]; [@B34]; [@B24]; [@B64]), while another study revealed upregulation of HERV-W ENV transcripts in plasma samples of SCZ patients ([@B31]). Moreover, a new study provides evidence that, in early stages of this disease, HERV-K methylation in peripheral blood is reduced ([@B45]). Of note, these observations contradict an earlier report suggesting that HERV-W expression is reduced in SCZ patients ([@B77]). The disparity between these reports may reflect different experimental approaches or a differential use of anti-psychotic medications in SCZ patients.

Mechanisms of HERV Activation {#s2}
=============================

It is known that silenced HERVs can be specifically activated and expressed in several neurological conditions based on complex underlying activation mechanisms. In this regard, numerous studies have established links between HERV activation and infections with viruses such as the Epstein Barr virus (EBV). In this context, EBV glycoprotein350 (EBVgp350) was found to trigger expression of HERV-W ENV in blood cells and astrocytes, possibly contributing to the onset of MS ([@B49]; [@B47]). Likewise, EBV was also shown to trigger HERV-K expression ([@B71]). Similar activation mechanisms were demonstrated for *Herpesviridae* HSV1 and HHV6 ([@B65]; [@B69]; [@B9]; [@B11]), providing a possible underlying mechanism explaining the well-established epidemiological link between these viruses and the susceptibility for MS. In addition, a direct involvement of the human immunodeficiency virus (HIV) Tat protein in activating HERV-W ENV in peripheral blood mononuclear cells (PBMCs), monocyte/macrophages, and astrocytes was described ([@B74]). Of note, in monocytes, HIV Tat inhibits the expression of syncytin-1, whereas in differentiated macrophages it is stimulated ([@B74]). In this regard it is important to note that HERV-K plasma levels were found to positively and negatively correlate with HIV infection and antiretroviral therapy, respectively ([@B8]). Whether HIV infection as such or antiretroviral treatment account for this observation is currently debated.

Yet, another important activator of HERV expression is the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) signaling pathway, based on an earlier report demonstrating that the pro-inflammatory cytokine tumor necrosis factor (TNF) α can stimulate the, at that time so-called, ERVWE1/syncytin promoter *via* NF-κB ([@B46]). Similarly, HERV-K expression was also shown to respond to TNFα/NF-κB signaling ([@B39]; [@B52]; [@B51]). Such signaling could be part of a regulatory feedback loop, taking into account that HERV long terminal repeat (LTR)-sequences act as promoters for pro-inflammatory cytokine genes ([@B32]).

In human SH-SY5Y neuroblastoma cells, caffeine and aspirin were shown to induce HERV-W ENV and GAG (group-specific antigen) transcription, providing a possible link between environmental factors, drugs, and endogenous virus activation ([@B42]). Whether such exogenous triggers can also affect HERV-W induction in myeloid cells, which are highly relevant for MS ([@B36]; [@B75]), remains to be demonstrated. Regarding ALS, TAR DNA binding protein 43 (TDP43), which is involved in the sporadic form of the disease ([@B44]), was found to bind to LTR sequences, leading to the expression and accumulation of HERV-K ([@B39]; [@B50]). A further contribution to HERV-W activation in MS was proposed to be mediated *via* endoplasmic reticulum (ER) stress ([@B15]). Finally, progerin, a nuclear protein involved in the accelerated aging Hutchinson--Gilford progeria syndrome, was found to strongly downregulate transcription of all classes of repetitive sequences including HERVs in dopaminergic neurons generated from induced pluripotent stem cells ([@B4]). Whether corresponding lessons can be learned in light of neurodegeneration in MS or ALS needs to be shown in future. Of note, progerin was also shown to impair the nuclear factor erythroid 2--related factor 2 (Nrf2)-mediated anti-oxidative response ([@B37]), a mechanism implicated in MS neuroprotection ([@B40]).

HERV Effects Exerted on Neural Cells {#s3}
====================================

Neurons {#s3_1}
-------

A potential HERV impact on neurons was studied in mice using experimental overexpression of the HERV-K ENV protein, mimicking its expression in cortical and spinal neurons of ALS patients. These transgenic mice showed severe signs of neurodegeneration with progressive motor dysfunction, motor cortex volume loss, decreased synaptic activity, and spine abnormalities ([@B39]). Such a phenotype implies that either endogenous damage pathways are activated or ENV protein leakage results in surface receptor activation, leading to autocrine or paracrine cell activation. CRISPR/Cas9 technology was recently used to disrupt the HERV-K ENV gene in human prostate cancer cells. By depleting ENV transcripts and proteins, this modification led to the downregulation of the above-mentioned important regulator TDP-43 (see [**Figure 1**](#f1){ref-type="fig"}; [@B33]). Given the formation of neurotoxic TDP-43 deposits in ALS neurons and TDP-43's implication in HERV-K activation ([@B19]), this study provides yet more evidence for a role of ENV proteins in neurodegeneration. This view might, however, be challenged by the observation that HERV-K ENV overexpression in neuronal cells increased their viability and prevented neurotoxicity mediated by the HIV-1 Vpr protein ([@B7]). This study was based on the fact that HERV-K and TDP-43 constitute an important neuropathological overlap between ALS and HIV encephalitis but might not be representative for MS- or ALS-related degeneration processes. To what degree inactivation of HERV-K might also be achieved *via* epigenetic modulators such as TRIM28 remains to be shown. In neural progenitor cells, TRIM28 acts a corepressor mediating transcriptional silencing. Its deletion resulted in induction of two groups of endogenous retroviruses IAP1 and MMERVK10C ([@B21]). Finally, in neuroblastoma cells, HERV-W ENV overexpression was reported to activate the TRPC3 channel to regulate calcium influx and to depress the SCZ relevant DISC1 protein ([@B12]). Whether this observation truly reflects cellular expression and consequences in neuropsychiatric disorders including non-transformed neuronal cells and whether it can specifically be attributed to the envelope of HERV-W remain to be studied in future.

![HERV-mediated effects on neural cells. This illustration summarizes origin and observed molecular effects of HERW-W and HERV-K on cells of the central nervous system. Arrow starting points indicate cellular sources of HERV particles or proteins (red dots), whereas arrowheads point to influenced cell types. Modulated processes are shown in gray boxes, and regulated molecules are highlighted in red next to each cell type. The question mark next to TDP-43 refers to its postulated regulation in neurons. Whether microglia and astroglia respond to HERVs in an auto- and/or paracrine way and whether neurons react to internal and/or extracellular HERVs remains to be shown. OPCs: oligodendroglial progenitor cells; NO: nitric oxide; CRP: C-reactive protein; BDNF: brain-derived neurotrophic factor; DRD3: dopamine receptor D~3~; TRPC3: short transient receptor potential channel 3; DISC1: disrupted in schizophrenia 1; TDP-43: TAR DNA-binding protein 43.](fgene-10-00655-g001){#f1}

Glial Cells {#s4}
===========

Expression of HERV-W ENV has mainly been observed in myeloid cells, i.e., monocytes/macrophages and microglia in MS patient tissues, while there is scarce evidence pointing to ENV expression by astrocytes ([@B63]; [@B36]; [@B75]). As of now, it is still unclear whether there is direct astroglial expression or if astroglia only bind or internalize ENV protein. However, signs of astroglial expression have also been gathered upon activation by EBV ([@B49]). Observations on the related syncytin-1 revealed induced astrocytic release of redox reactants, which are cytotoxic to oligodendrocytes ([@B3]), possibly acting *via* ASCT1 activation (see [**Figure 1**](#f1){ref-type="fig"}; [@B2]). In this regard, however, it must be stated that this study did not distinguished between the pathological HERV-W and the physiological syncytin-1. Furthermore, syncytin-1 overexpression in human microglia and astroglia was reported to activate the inflammatory marker CRP *via* TLR3 signaling ([@B76]), notably a receptor that is known to bind double-stranded RNA but is prone to nucleic acid artifacts in transfection experiments. In addition to the above-mentioned observations in neuroblastoma cells, overexpression of HERV-W ENV in human glioma cells was reported to induce expression of SCZ-linked genes encoding brain-derived neurotrophic factor (BDNF) and dopamine receptor D3 (DRD3; [@B31]), whereas the endogenous retroviral insert hsERVPRODH was found to act as a tissue-specific enhancer for the proline dehydrogenase 1 (PRODH), a candidate gene for SCZ susceptibility ([@B70]).

In the context of MS, stimulation of rat oligodendroglial progenitor cells (OPCs) with HERV-W ENV protein was found to impair their differentiation and to interfere with axon myelination ([@B36]; [@B28]). This effect is based on TLR4 activation and the subsequent induction of nitrosative stress (see [**Figure 1**](#f1){ref-type="fig"}). The HERV-W ENV-targeted therapeutic antibody GNbAC1 was initially developed to neutralize ENV-dependent activation of immune cells, yet was also revealed to be active in rescuing oligodendroglial differentiation ([@B35]) as well as myelination *in vitro* ([@B28]). Of note, in relapsing MS patients, a phase 2b clinical trial using GNbAC1 has been conducted (CHANGE-MS, NCT02782858). It therefore remains to be shown to what degree clinical results reflect these preclinical findings and whether MS patients show beneficial effects on remyelination or attenuated neurodegeneration. Moreover, interfering with TLR4 surface exposition by blocking of the vascular ATPase was also found to neutralize the ENV-dependent effect on OPC differentiation and axonal myelination ([@B28]). With regard to peripheral nervous system inflammatory damage, HERV-W ENV protein can also be detected in Schwann cells of CIDP patients. Cultured human Schwann cells exposed to or transfected with an ENV expression vector showed increased IL-6 and decreased CXCL10 transcript levels ([@B22]), hence showing signs of altered immunocompetence in the peripheral nerve ([@B73]). Likewise, this activation could be neutralized *via* the GNbAC1 antibody ([@B22]). To what degree HERV-W ENV protein-mediated activation also modulates the capacity of Schwann cells to de- and redifferentiate and whether it could therefore affect PNS repair remains to be shown.

Although microglial cells are currently viewed as a relevant source of HERV-W ENV protein in the diseased CNS, additional autocrine/paracrine effects on these myeloid cells cannot be excluded and warrant further investigations. In this regard, it is worth mentioning that nitric oxide (NO) production and cellular migration were found to be affected in response to stimulation of rat microglia with a recombinant ENV protein ([@B78]).

Finally, a role of HERV-W ENV in diminishing myelin repair is also important in light of the reproduced documentation on its expression in MS but also considering recent findings implying an implication in molecular mimicry. In this regard, several groups provided evidence of similarities between HERV-W ENV and myelin oligodendrocyte glycoprotein (MOG). This molecular mimicry may be an underlying mechanism leading to or fueling autoimmunity ([@B16]; [@B66]; [@B13]). To what degree such molecular similarities also disturb successful maturation of resident OPCs required for myelin repair needs to be investigated in future.

Conclusion {#s5}
==========

We here present collected evidence that endogenous retroviral elements acting either as viral particles or *via* their proteins influence neural cells in the context of degenerative CNS diseases. Once thought to be primarily involved in cell transformation ([@B29]) and inflammation ([@B58]), emerging data suggests a direct role of these elements in glial and neuronal injury, which in fact goes beyond previous descriptions on the activity of a gliotoxin ([@B55]). In light of additional observations on the role of ERVs in regulating stem cell potential and fate acquisition ([@B27]), the findings describing impacts on committed or mature cells of the CNS are probably not too surprising but warrant future investigations, even more so since neural stem cells are also involved in brain pathology and regeneration. Moreover, the currently still unmet clinical need to effectively treat neurodegeneration necessitates novel therapeutic approaches. Whether similar mechanisms also apply to activation of transposable elements implicated in, for example, chronic fatigue syndrome (CFS; [@B1]) and to what degree currently used neutralizing antibodies can be exploited in order to prevent neural cell activation and/or neurodegeneration needs to be elucidated in the future. In this regard, it remains to be shown whether HERV-employed signaling pathways and epigenetic silencing mechanisms can be used for biomedical translation.
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